Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) generates a steady flow of news as a fully integrated, commercial-stage biotechnology company with both marketed products and a broad development pipeline. News coverage for Tonix often centers on its FDA-approved fibromyalgia treatment TONMYA, its acute migraine products Zembrace SymTouch and Tosymra, and updates on clinical and regulatory milestones across central nervous system, immunology, rare disease and infectious disease programs.
Investors following TNXP news can expect announcements on commercial launches, market access decisions, and distribution arrangements for TONMYA, as well as prescription trends and formulary placements for its migraine therapies. The company also regularly reports progress on TNX-102 SL in indications such as acute stress-related conditions and major depressive disorder, including IND clearances and the design of potentially pivotal Phase 2 studies.
Tonix’s immunology and infectious disease work contributes additional news items, including collaborations with academic centers like Massachusetts General Hospital for TNX-1500 in kidney transplantation, and development plans for TNX-4800, a monoclonal antibody designed for seasonal prevention of Lyme disease. Licensing transactions, such as the acquisition of TNX-4900 for chronic neuropathic pain from Rutgers University, and government-supported projects like the DTRA-backed antiviral TNX-4200, are also common themes in company press releases.
This TNXP news page aggregates company-issued updates and related coverage so readers can quickly review developments in Tonix’s commercial operations, clinical pipeline, financing activities, and strategic collaborations. For investors and observers tracking biotech catalysts, revisiting this page provides a concise way to monitor how Tonix’s programs and capital markets actions evolve over time.
Tonix Pharmaceuticals (Nasdaq: TNXP) has initiated a Phase 2 clinical trial for TNX-1300, a potential treatment for acute cocaine intoxication. The study, named CATALYST, is a single-blind, placebo-controlled trial conducted in emergency departments across six U.S. academic medical centers. TNX-1300 is a recombinant enzyme designed to rapidly degrade cocaine in users. The trial will enroll approximately 60 subjects, comparing a 200 mg dose of TNX-1300 to placebo plus standard care.
Key points:
- TNX-1300 has received Breakthrough Therapy designation from the FDA
- The primary endpoint is reduction in systolic blood pressure after 60 minutes
- Topline results are expected in the first half of 2025
- In 2022, over 27,569 U.S. deaths involved cocaine overdose
- Currently, there is no FDA-approved treatment for cocaine intoxication
Tonix Pharmaceuticals (TNXP) reported Q2 2024 financial results and operational highlights. Key points include:
- On track to submit NDA for TNX-102 SL for fibromyalgia in H2 2024
- FDA granted Fast Track designation for TNX-102 SL
- Awarded $34 million DoD contract for broad-spectrum antiviral drug development
- Q2 2024 net product revenue: $2.2 million
- Cash and equivalents: $4.2 million as of June 30, 2024
- Net loss: $78.8 million ($19.28 per share)
The company is advancing its pipeline, including TNX-102 SL for fibromyalgia, TNX-1300 for cocaine intoxication, and TNX-1500 for organ transplant rejection. Tonix is also developing broad-spectrum antivirals and vaccines for mpox and COVID-19.
Tonix Pharmaceuticals (NASDAQ: TNXP) is advancing development of TNX-801, a single-dose live attenuated virus vaccine candidate for mpox and smallpox. This comes as the WHO declares the mpox outbreak in Africa a global health emergency. Key points:
1. TNX-801 demonstrated efficacy in protecting animals from lethal challenge with monkeypox virus.
2. The vaccine is designed to provide long-term protection with one dose.
3. Clade II mpox is now endemic in the U.S. with >30,000 cases since May 2022.
4. Tonix's vaccine platform has been selected by NIH's Project NextGen for clinical testing.
5. TNX-801 showed potential to prevent clinical disease, lesions, and decrease viral shedding in non-human primates.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman will present at the Summer 2024 Virtual Investor Summit on August 20, 2024, at 11:00 a.m. ET. The presentation will be available via webcast on the company's website. Tonix is a fully-integrated biopharmaceutical company with marketed products and a development pipeline focused on central nervous system (CNS) disorders.
Key highlights include:
- Plans to submit a New Drug Application (NDA) for TNX-102 SL for fibromyalgia management in the second half of 2024
- FDA Fast Track designation for TNX-102 SL
- Development of TNX-1300 for cocaine intoxication with Breakthrough Therapy designation
- Immunology portfolio including TNX-1500 for organ transplant rejection and autoimmune diseases
- Commercial products: Zembrace SymTouch and Tosymra for acute migraine treatment
Tonix Pharmaceuticals (TNXP) presented data on TNX-102 SL, a sublingual cyclobenzaprine HCl treatment for fibromyalgia, at the IASP 2024 World Congress on Pain. The Phase 3 RESILIENT study showed statistically significant improvement in the primary endpoint of fibromyalgia nociplastic pain and all six key secondary endpoints, including sleep quality. Post hoc analyses revealed strong correlations between improvements in pain and sleep quality.
TNX-102 SL, designed as a bedtime treatment to target non-restorative sleep, has received Fast Track designation from the FDA for fibromyalgia management. Tonix plans to submit an NDA in the second half of 2024. The treatment was well-tolerated with no new safety signals observed, potentially becoming the first new fibromyalgia treatment option in 15 years.
Tonix Pharmaceuticals (TNXP) has published a research paper in Microorganisms highlighting their proprietary high-throughput, high-content imaging technology for screening convalescent sera. This technology can be used to generate neutralizing, fully-human monoclonal antibodies against SARS-CoV-2 variants and potentially other pathogens.
The company's CEO, Seth Lederman, emphasized Tonix's capabilities in developing antibodies to counter COVID-19 and its variants. Tonix is also developing TNX-801, a live-virus vaccine for mpox and smallpox, and TNX-1800, a potential COVID-19 vaccine selected for NIH's Project NextGen. Additionally, Tonix is working on TNX-4200, an oral CD45 antagonist with broad-spectrum antiviral efficacy, supported by a $34 million DoD/DTRA contract.
The FDA has granted Fast Track designation to Tonix Pharmaceuticals (NASDAQ:TNXP) for TNX-102 SL, a drug candidate for managing fibromyalgia. This recognition underscores fibromyalgia as a serious condition affecting over 10 million Americans. The global fibromyalgia treatment market is projected to reach $3.86 billion by 2031, growing at a 3.3% CAGR. TNX-102 SL, a non-addictive sublingual formulation of cyclobenzaprine hydrochloride, showed significant improvement in fibromyalgia pain in Phase 3 trials. Tonix plans to submit a New Drug Application (NDA) in the second half of 2024, potentially becoming the first new fibromyalgia pharmacotherapy in over 15 years.
Tonix Pharmaceuticals (TNXP) reports potential positive impact on the fibromyalgia market for Tonmya™ due to the new definition of Long COVID by the U.S. National Academies (NASEM). Key points:
1. Fibromyalgia is now recognized as a 'diagnosable condition' in Long COVID patients.
2. This may expand the addressable market for Tonmya beyond pre-pandemic estimates.
3. Tonmya, a non-opioid analgesic for fibromyalgia, has Fast Track designation.
4. NDA submission target: second half of 2024, potential FDA approval in 2025.
5. Estimated 14 million U.S. adults suffer from Long COVID, with over 40% potentially presenting fibromyalgia-like symptoms.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced a poster presentation at the IASP 2024 World Congress on Pain, highlighting statistically significant Phase 3 results of Tonmya™ for fibromyalgia management. The presentation, scheduled for August 7, 2024, will focus on targeting non-restorative sleep with TNX-102 SL, showing consistent syndromic improvement. Tonmya has received FDA Fast Track Designation, and Tonix plans to submit a New Drug Application (NDA) in the second half of 2024.
Tonix is developing a portfolio of central nervous system (CNS) disorders treatments, including TNX-1300 for cocaine intoxication with Breakthrough Therapy designation. The company also has immunology and rare disease candidates in development. Tonix Medicines, their commercial subsidiary, markets Zembrace® SymTouch® and Tosymra® for acute migraine treatment.
Tonix Pharmaceuticals (Nasdaq: TNXP) has received Fast Track designation from the FDA for Tonmya™, its non-opioid analgesic drug for fibromyalgia. This designation recognizes fibromyalgia as a serious condition affecting over 10 million U.S. adults and aims to expedite FDA review. Tonix plans to submit a New Drug Application (NDA) in the second half of 2024, with potential market entry in 2025. If approved, Tonmya could be the first new fibromyalgia drug in over 15 years. The company is positioning Tonmya as a first-line, long-term daily treatment option. Fast Track status allows for more frequent FDA interactions and the possibility of Priority Review, potentially accelerating the approval process.